<?xml version='1.0' encoding='utf-8'?>
<document id="20091169"><sentence text="A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors."><entity charOffset="55-64" id="DDI-PubMed.20091169.s1.e0" text="vatalanib" /><entity charOffset="104-114" id="DDI-PubMed.20091169.s1.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.20091169.s1.e0" e2="DDI-PubMed.20091169.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20091169.s1.e0" e2="DDI-PubMed.20091169.s1.e1" /></sentence><sentence text="To define the maximum-tolerated dose (MTD) for weekly paclitaxel administered in combination with daily vatalanib (PTK787/ZK 222584, PTK/ZK) and assess for a drug-drug interaction"><entity charOffset="54-64" id="DDI-PubMed.20091169.s2.e0" text="paclitaxel" /><entity charOffset="104-113" id="DDI-PubMed.20091169.s2.e1" text="vatalanib" /><pair ddi="false" e1="DDI-PubMed.20091169.s2.e0" e2="DDI-PubMed.20091169.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20091169.s2.e0" e2="DDI-PubMed.20091169.s2.e1" /></sentence><sentence text="" /><sentence text="Patients were treated with escalating doses of weekly paclitaxel (75-85 mg/m(2)), and daily PTK/ZK (250-1,000 mg)"><entity charOffset="54-64" id="DDI-PubMed.20091169.s4.e0" text="paclitaxel" /></sentence><sentence text=" During the first cycle only, paclitaxel was given on days 1 and 15, and PTK/ZK on days 3-28"><entity charOffset="30-40" id="DDI-PubMed.20091169.s5.e0" text="paclitaxel" /></sentence><sentence text=" Pharmacokinetic studies were conducted on cycle 1 days 1 and 15 for paclitaxel, and on cycle 1 day 15 for PTK/ZK"><entity charOffset="69-79" id="DDI-PubMed.20091169.s6.e0" text="paclitaxel" /></sentence><sentence text=" Therapy was given until disease progression" /><sentence text="" /><sentence text="Twenty-seven patients were accrued to four dose levels" /><sentence text=" Two of five patients treated with paclitaxel 85 mg/m(2) and PTK/ZK 1,000 mg had Grade 3 transaminase elevation as dose-limiting toxicity"><entity charOffset="35-45" id="DDI-PubMed.20091169.s10.e0" text="paclitaxel" /></sentence><sentence text=" Paired PK analyses demonstrated a significant increase in paclitaxel clearance on day 15 (p = 0"><entity charOffset="59-69" id="DDI-PubMed.20091169.s11.e0" text="paclitaxel" /></sentence><sentence text="006)" /><sentence text=" Activity included one partial response and 11 patients with stable disease &gt; or =4 months, including patients previously treated with paclitaxel"><entity charOffset="135-145" id="DDI-PubMed.20091169.s13.e0" text="paclitaxel" /></sentence><sentence text="" /><sentence text="The MTD for weekly paclitaxel plus daily PTK/ZK is 75 mg/m(2) and 750 mg"><entity charOffset="19-29" id="DDI-PubMed.20091169.s15.e0" text="paclitaxel" /></sentence><sentence text=" PK analysis revealed a significant drug-drug interaction, with an increase in paclitaxel clearance"><entity charOffset="79-89" id="DDI-PubMed.20091169.s16.e0" text="paclitaxel" /></sentence><sentence text=" This combination was well tolerated with evidence of anti-cancer activity and provides guidance for phase 2 planning" /><sentence text="" /></document>